Press Release

Oct, 31 2023

Innovative Injectable Drug Delivery Devices Paving the Way for Precise and Painless Treatments

The injectable drug delivery devices market offers numerous advantages, including precise dosage administration, rapid drug absorption, and increased patient compliance. Among these devices, autoinjectors are the dominating segment. Autoinjectors are user-friendly, allowing patients to self-administer medications easily, particularly for conditions such as rheumatoid arthritis and diabetes. This category simplifies treatment regimens, enhances convenience, and reduces the need for healthcare facility visits. As a result, autoinjectors play a pivotal role in driving growth within the injectable drug delivery devices market.

Access full report @ https://www.databridgemarketresearch.com/reports/china-injectable-drug-delivery-devices-market

Data Bridge Market Research analyses that the China Injectable Drug Delivery Devices Market tends to be around a CAGR of 18% in the forecast period of 2023-2030. The market is valued at USD 52,164.9 million in 2022, and it will grow up to USD 1,96,080.51 million by 2030. Biologic therapies are highly complex and sensitive drugs, necessitating precise administration to ensure their effectiveness and safety. Injectable drug delivery devices offer the control and accuracy required for the successful delivery of these specialized treatments.

Key Findings of the Study

China Injectable Drug Delivery Devices Market

The rise in chronic diseases is expected to drive the market's growth rate

The rising incidence of chronic illnesses, such as diabetes, cardiovascular diseases, and autoimmune disorders, underscores the need for drug delivery methods that are not only effective but also convenient for patients. Injectable drug delivery devices provide a reliable means to administer medications with precision, ensuring that patients receive the necessary treatment consistently. This convenience is crucial for managing chronic conditions, improving patient adherence to prescribed therapies, and ultimately enhancing the quality of life for individuals living with these diseases.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product Type (Formulations, Devices), Usage Pattern (Curative Care, Immunization, Other Usage Pattern), Mode of Administration (Skin, Circulatory/ Muskoskeletal, Organs, Central Nervous System), Application (Hormonal Disorders, Oncology, Autoimmune Disorders, Orphan Diseases, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

China

Market Players Covered

Baxter (U.S.), BD (U.S.), China Meheco Group Co., Ltd (China), Elcam Medical (U.S.), Lilly (U.S.), Mylan N.V. (U.S.), Novo Nordisk A/S (Denmark), Pfizer Inc (U.S.), Agouron Pharmaceuticals (U.S.), AHP Holdings B.V. (Netherlands), Alacer Corp. (U.S.), Alpharma Pharmaceuticals LLC (U.S.), Bioren, LLC (U.S.), G.D. Searle & Co. Limited (U.K.)

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The China injectable drug delivery devices market is segmented on the basis of product type, application, usage pattern, mode of administration, end user, and distribution channel.

  • On the basis of product type, the China injectable drug delivery devices market is segmented into formulations, and devices.
  • On the basis of application, the China injectable drug delivery devices market is segmented into hormonal disorders, oncology, autoimmune disorders, orphan diseases, and others.
  • On the basis of usage pattern, the China injectable drug delivery devices market is segmented into curative care, immunization, and other usage pattern.
  • On the basis of mode of administration, the China injectable drug delivery devices market is segmented into skin, circulatory/ muskoskeletal, organs, and central nervous system.
  • On the basis of end user, the China injectable drug delivery devices market is segmented into hospitals, homecare, specialty clinics, and others.
  • On the basis of distribution channel, the China injectable drug delivery devices market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy.

Major Players

Data Bridge Market Research recognizes the following companies as the China injectable drug delivery devices market players in China injectable drug delivery devices market are Baxter (U.S.), BD (U.S.), China Meheco Group Co., Ltd (China), Elcam Medical (U.S.), Lilly (U.S.), Mylan N.V. (U.S.), Novo Nordisk A/S (Denmark), Pfizer Inc (U.S.), Agouron Pharmaceuticals (U.S.).

China Injectable Drug Delivery Devices Market

Market Developments

  • In 2022, EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics achieved approval from China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) for YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg. This approval allows for the use of YUTIQ in the treatment of chronic non-infectious uveitis, a significant advancement in addressing this vision-threatening condition in China, providing an effective therapeutic option for patients suffering from this chronic eye inflammation.
  • In 2020, Sanofi and Regeneron Pharmaceuticals secured approval from China's National Medical Products Administration (NMPA) for Dupixent (dupilumab) as a treatment for adults with moderate to severe atopic dermatitis. Dupixent is available in China as a pre-filled syringe with a 300mg dose. This approval marked a significant milestone in providing an effective therapy for Chinese patients grappling with this chronic skin condition, offering them access to a novel treatment option for improved quality of life.

For more detailed information about the China injectable drug delivery devices market report, click here – https://www.databridgemarketresearch.com/reports/china-injectable-drug-delivery-devices-market


Client Testimonials